WO2004027424A1 - 蛍光化抗体を用いた蛍光分析方法 - Google Patents
蛍光化抗体を用いた蛍光分析方法 Download PDFInfo
- Publication number
- WO2004027424A1 WO2004027424A1 PCT/JP2003/011926 JP0311926W WO2004027424A1 WO 2004027424 A1 WO2004027424 A1 WO 2004027424A1 JP 0311926 W JP0311926 W JP 0311926W WO 2004027424 A1 WO2004027424 A1 WO 2004027424A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- substance
- dye
- measured
- concentration
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/345—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brevibacterium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Definitions
- the present invention relates to a fluorescence analysis method using a dye that changes from non-fluorescent to fluorescent when bound to an antibody.
- immunoassays using a fluorescent dye-labeled antibody have been developed as one of the methods that enable such analysis. That is, according to such an immunoassay, a highly selective analysis can be performed by a specific molecular recognition function by an antigen-antibody reaction, and a target substance can be selectively selected without removing contaminants by fluorescence analysis. It becomes possible to measure in a short time.
- the fluorescent dye-labeled antibody an antibody previously labeled with a fluorescent dye is generally used, and one substance (antigen) is specifically recognized by an antigen binding site.
- Hei 4-212,163 has two antigen-binding sites, one of which is raised against tissue plasminogen activator and the other is a fluorescent material or the like.
- a bispecific hybrid monoclonal antibody raised against a label is disclosed.
- Japanese Patent Application Laid-Open No. 9-53224 discloses an antibody against an antigen formed by adding a non-fluorescent dye to an immunological substance.
- 11-183477 discloses a binding substance (MG-labeled insulin) of insulin and malakite green (MG), A fluorescent immunoassay method for measuring a change in fluorescence intensity based on an antigen-antibody reaction with an anti-MG-Ins antibody, which has as an antigen, in the presence of insulin, is disclosed.
- the present inventor has a common technical knowledge of those skilled in the art that the antigen-antibody reaction is irreversible (for example, “Fluorome Noatse”, Kiyoshi Takai et al., Kodansha Scientific p. 57-58 (1985); K. Ichihara et al., Clinica Chimica Acta Vol. 98, p. 87-100 (1979); etc.). It was found that it was difficult to perform continuous analysis with.
- the present inventor has proposed that an antigen-antibody reaction between MG-labeled inulin and an anti-MG-Ins antibody described in Japanese Patent Application Laid-Open No.
- an antigen-antibody reaction between MG-labeled inulin and an anti-MG-Ins antibody described in Japanese Patent Application Laid-Open No.
- a competition reaction between insulin and MG labeling insulin occurs, and finally, almost all MG-labeled insulin occupies the inulin recognition site and reaches a steady state. That is, the competitive reaction between insulin and MG-labeled insulin is an irreversible reaction. Therefore, in an immunoassay utilizing such an antigen-antibody reaction, changes in the amount of a substance in a living body are continuously analyzed in real time. It has been found difficult.
- the present invention has been made in view of the above-mentioned problems of the related art, and provides a simple, highly sensitive, and real-time continuous method for in vivo substances using an antigen-antibody reaction.
- the purpose of the present invention is to provide a fluorescence analysis method capable of performing analysis (including imaging).
- the present inventors have conducted intensive studies to achieve the above object, and as a result, have found that the antibody described in Japanese Patent Application Laid-Open No. 9-53224, which has been invented by the present inventors and has already filed a patent application. That is, the antigen-antibody reaction using an antibody against an antigen formed by adding a non-fluorescent dye to an immunological substance in the presence of a non-fluorescent dye alone and an immunological substance alone is surprisingly reversible.
- the present inventors have further found that the above-mentioned object can be achieved by performing a fluorescence analysis utilizing such a reversible antigen-antibody reaction, and reached the present invention. did.
- the present invention relates to an antibody in which a part of the antigen-binding site recognizes a dye and the remaining part recognizes a substance to be measured, and when the antibody is recognized by the antibody and binds to the antibody.
- a calculating step for obtaining the concentration of the fluorescent compound is a calculating step for obtaining the concentration of the fluorescent compound.
- the dye and the substance to be measured are each subjected to the antigen-antibody reaction by an antigen-antibody reaction.
- the dye bound to the antibody changes from non-fluorescent to fluorescent.
- the binding of the dye to the antibody is affected by the amount of the co-existing analyte, so the intensity of the fluorescence emitted by the dye bound to the antibody is inhibited or enhanced according to the amount of the co-existing analyte. Is done. Therefore, in a solution in which the amounts of the dye and the antibody are constant, the fluorescence intensity and the concentration of the target substance are correlated.
- the measurement is performed from the actual measured fluorescence intensity.
- concentration of the target substance is required. Therefore, in the fluorescence analysis method of the present invention, highly specific analysis with high selectivity is possible due to the specific molecular recognition function by the antigen-antibody reaction, and impurities are removed by fluorescence analysis which is not easily affected by the impurities. At the same time, it is possible to selectively and simply measure the target substance.
- the antigen-antibody reaction according to the present invention that is, the binding reaction between the part that recognizes the dye in the antibody and the dye, and the binding between the part that recognizes the target substance in the antibody and the target substance
- the reaction is reversible, contrary to the common technical knowledge that the antigen-antibody reaction is irreversible, and the dye and the substance to be measured occupy a part of the antibody that recognizes the dye and the substance to be measured. Does not reach a steady state. It is possible to perform continuous analysis (including imaging) in real time by utilizing the fact that the fluorescence intensity fluctuates in response to the fluctuation of the amount.
- the fluorescence analysis method of the present invention after the calculating step, a further analyte solution is added to the mixed solution and mixed, and the measuring step and the calculating step are performed.
- the method may further include a continuous analysis step of repeatedly obtaining the concentration of the measurement target substance. By including such a continuous analysis step, it is possible to continuously analyze the concentration of the substance to be measured in real time.
- the calculating step includes a step of correcting the measured value according to a volume change accompanying the addition of the analyte solution to obtain a fluorescence intensity correction value; Obtaining a concentration of the substance to be measured in the mixed solution from the fluorescence intensity correction value based on a relationship between the correction value and the concentration of the substance to be measured in the mixed solution; Obtaining the concentration of the substance to be measured in the sample solution from the above.
- the fluorescence analysis method of the present invention is characterized in that the antigen-binding site partially recognizes a dye, and the remaining part partially recognizes a substance to be measured.
- Calibration curve generating step of obtaining the engagement may further comprise a.
- the calibration curve creating step corrects the measured value according to a volume change accompanying the addition of the standard solution to obtain a fluorescence intensity correction value
- the method includes a step of calculating a concentration of the measurement target substance, and a step of calculating a relationship between the fluorescence intensity correction value and the concentration of the measurement target substance in the mixed solution.
- a dye having a triphenylmethane structure and a dye having a diphenylmethane structure are preferable, and malachite green or auramine o is more preferable.
- the antibody according to the present invention includes (i) an antibody using a binding substance of the dye and the substance to be measured as an antigen, or (ii) an antibody recognized by the antibody.
- an antibody is used in which a structure necessary for changing from non-fluorescent to fluorescent when bound to the antibody is a dye in common with the dye and a binding substance of the measurement target substance as an antigen.
- an antibody in which the antibody is a binding substance between malachite green and the substance to be measured as an antigen and (ii) the antibody is malachite green. It is more preferable that the antibody is an antibody having a binding substance of green and the substance to be measured as an antigen, and the pigment is auramine O.
- the substance to be measured by the fluorescence analysis method of the present invention is selected from the group consisting of proteins, hormones, vitamins, bacteria, environmental pollutants, and pharmaceuticals to be subjected to immunoassay. Are preferred.
- FIG. 1 is a schematic diagram showing a G-measurement target substance complex as an antigen.
- FIG. 2 is a schematic diagram showing a state in which the antigen recognition site recognizes both MG and the substance to be measured.
- FIG. 3 is a schematic diagram showing an antigen-antibody reaction between MG and an antibody.
- FIG. 4 is a schematic diagram showing an antigen-antibody reaction between a substance to be measured and an antibody.
- FIG. 5 is a schematic diagram showing the antigen-antibody reaction of the antibody, MG, and the substance to be measured.
- FIG. 6A and FIG. 6B are schematic diagrams each showing the effect of the substance to be measured on the antigen-antibody reaction between the antibody and the MG.
- FIG. 7 is a schematic diagram showing that the half-life of MG-antibody is longer than that of one antibody to be measured.
- FIG. 8 is a flowchart showing a preferred embodiment of a method for preparing a calibration curve according to the present invention.
- FIG. 9 is a flow chart showing a preferred embodiment of the fluorescence analysis method of the present invention.
- FIG. 10 is a graph showing the antibody titer of anti-MG_Ins serum. [0027] FIG. 11 shows the results obtained by reacting anti-MG—Ins Fab with MG.
- FIG. 6 is a graph showing a G fluorescence spectrum.
- FIG. 12 is a graph showing the relationship between MG concentration and MG fluorescence intensity.
- FIG. 13 is a graph showing the relationship (calibration curve) between the concentration of inulin and the MG fluorescence intensity.
- FIG. 14 is a graph showing the fluorescence spectrum of AO when anti-MG-InsIgG was reacted with AO.
- FIG. 15 is a graph showing the relationship (calibration curve) between insulin concentration and AO fluorescence intensity.
- FIG. 16 shows the repeated addition of inulin and anti-insulin IgG. 6 is a graph showing a change in AO fluorescence intensity at the time of the above.
- the dye used in the present invention is not particularly limited as long as it is non-fluorescent in a normal solvent such as water and turns fluorescent when bound to an antibody described later.
- the term "non-fluorescent” means substantially non-fluorescent. Under normal measurement conditions, it does not show a fluorescent spectrum or shows only extremely weak fluorescence. It is preferable that fluorescence analysis (fluorescence spectroscopy) is not possible due to such factors (Yasuharu Nishikawa et al., Fluorescent Phosphorescence Spectroscopy Kyoritsu Shuppan, page 30, 1989).
- a dye having a fluorescence quantum yield of less than 1% under specific conditions is preferable, and a dye having a fluorescence quantum yield of 0.01% or less under specific conditions is preferred. More preferred.
- a dye when binds to an antibody, it changes from non-fluorescent to fluorescent, which means that a dye that is not substantially fluorescent binds to the antibody and becomes fluorescent (fluorescence increases).
- fluorescence analysis can be performed by obtaining an analysis sensitivity higher than that obtained by ordinary fluorescence analysis, and the fluorescence quantum yield of the dye is extremely small under ordinary measurement conditions (eg, 0.01% From the following), it is preferable that the fluorescence quantum yield is changed to a large state (eg, 1% or more) by binding (interaction) with the antibody by the treatment according to the present invention.
- the increase in the fluorescence intensity when the dye changes from non-fluorescent to fluorescent is preferably such that the fluorescence quantum yield increases by at least 10 times or more, and at least 100 times or more. More preferably, it is particularly preferable to increase at least 100 times or more.
- the dye usable in the present invention does not necessarily have to have absorption in the visible region (having an absorption maximum at 350 nm or more), but has ultraviolet absorption. (Having an absorption maximum at 50 nm or less), or having an absorption band extending to the visible region.
- the molecular structure of the dye that can be used in the present invention is not particularly limited, and those containing various chromophores (chromophores) can be used. It is desirable to include one.
- a dye having a triphenylmethane skeleton in its molecular structure for example, see “Kodan Hata Handbook” edited by Kodansha Scientific and Shin Okawara) is preferable.
- a suitable triphenylmethane dye malachite green (MG) having the following chemical structure is particularly preferred.
- a dye having a diphenylmethane skeleton in its molecular structure is also preferable.
- Auramine O (AO) having the following chemical structure is particularly preferred as the diphenylmethane dye.
- C CVJ (9- (dicyanovinyl) julolidine) dyes, ANS (anilinonaphthalene) dyes, TNS (p-toluidinylnaphthalene) dyes, and DNP (2,4-dinito mouth funinyl) dyes are also preferably used. It is.
- the substance to be measured applicable to the fluorescence analysis method of the present invention is not particularly limited as long as the substance (complex) bound to the dye functions as an antigen.
- the substance to be measured according to the present invention is not necessarily required to be an immunological substance. That is, an antibody is generally not obtained for a substance with low tolerance and immunological tolerance, but in the present invention, a complex in which a dye that is an artificial compound is bound to a substance to be measured is used as an antigen.
- a complex in which a dye that is an artificial compound is bound to a substance to be measured is used as an antigen.
- the substance to be measured itself is a tolerant substance, even if it is a substance with low antigenicity, it is highly likely that the complex with the dye will be immunized, and it is possible to obtain the antibody by the method described below. is there.
- a wide range of substances other than inorganic ions and organic ions can be applied as a substance to be measured, and in particular, proteins (such as insulin, etc.) to be subjected to immunoassay ), Hormones, vitamins, bacteria, environment Substances selected from the group consisting of contaminants and pharmaceuticals are preferred as analytes.
- Antibodies can be prepared. That is, even if the substance to be measured is a substance that is tolerant to the animal to be immunized (such as an in vivo component of the animal species), the antibody described below can be prepared. This is because the antigen according to the present invention is not the substance to be measured itself, but an artificial substance obtained by cross-linking an artificial dye. Further, even if the target substance itself does not have a sufficient molecular weight to become an antigen, a carrier having an antigenicity with respect to the complex of the dye and the target substance is further added. A covalently crosslinked product may be prepared and used as an antigen. Even in this case, the following antibodies are obtained in which the antigen recognition site recognizes both the dye and the substance to be measured.
- a part of the antigen binding site recognizes a dye and the other part recognizes a substance to be measured. That is, in the antibody according to the present invention, one antigen binding site is spatially decomposed into a plurality of portions, some of which recognize a dye, and the other of which recognizes a substance to be measured. As described above, a technique in which one antigen binding site has a plurality of different functions has not existed conventionally, and was first discovered by the present inventors.
- Such an antibody according to the present invention is suitably formed using, as an antigen, a binding substance between the dye used in the fluorescence analysis method of the present invention and the substance to be measured, and is used for, for example, analysis.
- the dye is malachite green
- the antibody is preferably an antibody having a binding substance between malachite green and a substance to be measured as an antigen.
- the dye used for the analysis and the dye for obtaining the antibody are the same. It is not always necessary to use a dye which has a structure necessary for the structure to be changed from non-fluorescent to fluorescent when recognized by the antibody and bound to the antibody. As a combination of dyes having such a common structure, there is a combination of malachite green and auramin o. Therefore, for example, when the dye used in the analysis is olamine O, the antibody may be an antibody having a binding substance of malachite green and the substance to be measured as an antigen.
- the method for producing the complex (antigen) of the dye and the substance to be measured according to the present invention is not particularly limited.
- the above-mentioned substance to be measured and the dye are mixed by stirring for a predetermined time, and gel filtration chromatography is used.
- gel filtration chromatography is used.
- the antigen obtained for example, by using a purification means utilizing an immune reaction (Kouichiro Kawashima (translation) "Introduction to Imnoassy", Nanzan-do, 70 pages, 1987). Further, the concentration of the obtained antigen can be quantified by, for example, the Lowry method.
- the antibody according to the present invention can be preferably prepared by the immunization step described below. That is, the antibody according to the present invention can be prepared by administering the complex (antigen) to an immunized animal, collecting blood from the immunized animal, and separating antiserum from the blood. It is.
- the immunized animal to which the complex (antigen) is administered is not particularly limited, but egrets, guinea pigs and the like can be suitably used.
- usable immunoadjuvants are not particularly limited, but common Freund's incomplete adjuvant, aluminum adjuvant and the like can be suitably used.
- guinea pigs subcutaneous injection, intraperitoneal injection and the like can be suitably used.
- booster immunization should be performed, and a test sample should be taken to check the antibody titer. It is possible to do.
- the method of separating the collected antiserum is not particularly limited, and it is possible to separate the serum by a general method, for example, by coagulating blood collected and then centrifuging.
- the specific antibody activity of the obtained antiserum to the complex (antigen) can be preferably measured by an enzyme immunoreaction or the like. (Illustration Fluorescent antibody method, its principle and technology, and application 1) Akira Kawao, P. 135-138, Soft Science Inc. (1 983).
- the antibody in the above antiserum may be used, but the IgG fraction obtained by purifying the antiserum may be used as the antibody.
- the method for purifying the IgG fraction from such antiserum is not particularly limited, and a salting-out method, a gel filtration method, an ion-exchange chromatography method and the like can be preferably used, and a protein A method is particularly preferable. Noh.
- the obtained IgG fraction may be further concentrated by a centrifugation method, and thus the IgG fraction can be adjusted to a predetermined concentration.
- an antigen-binding fragment (Fab) prepared from the IgG fraction as an antibody.
- the precipitation of an immune complex with the substance to be measured tends to be more reliably prevented.
- the method for preparing the antigen-binding fragment (Fab) from such an IgG fraction is not particularly limited.
- the IgG-fraction is digested with a digestive enzyme (eg, papain digestive enzyme) to digest the antigen-binding fragment. (F ab) can be obtained.
- the obtained antigen-binding fragment (Fab) is preferably purified by an immunoprecipitation method such as the protein A method, and may be further concentrated by a centrifugation method. In this way, the antigen-binding fragment (Fab) can be adjusted to a predetermined concentration.
- the antibody, the dye, and the substance to be measured are dissolved in a solution.
- the dye and the substance to be measured each bind to the antibody by an antigen-antibody reaction, and the dye bound to the antibody changes from non-fluorescent to fluorescent.
- the binding of the dye to the antibody is affected by the amount of the co-existing analyte, and the intensity of the fluorescence emitted by the dye bound to the antibody is inhibited or enhanced according to the amount of the co-existing analyte.
- the antigen-antibody reaction according to the present invention is reversible, contrary to the conventional general knowledge that the antigen-antibody reaction is irreversible, and the fluorescence intensity fluctuates according to the fluctuation of the amount of the substance to be measured.
- the present inventors presume that the principle of such a fluorescence analysis method of the present invention is as follows. The case where malachite green (hereinafter, referred to as MG) is used as a representative of the dye used in the present invention will be described as an example.
- MG malachite green
- both MG and the substance to be measured bind to the antigen-binding site of the antibody as shown in FIG.
- both the MG and the substance to be measured fall within the antigen-binding site, it is presumed to be the most stable because the state shown in FIG. 2 in which the MG-substance complex is bound to the antibody is close to that.
- the substance to be measured may affect the MG-antibody binding, and the MG may affect the binding between the substance to be measured and the antibody. It is presumed that the reaction kinetics is determined by the positions occupied by the MG and the analyte in the antigen-binding site (which are deeper) and the dissociation rate constants of each. For example,
- MG dissociates faster
- Augmentation is less likely to occur and inhibition becomes dominant.
- the present invention utilizes this phenomenon.
- the degree of inhibition or enhancement depends on the amount of the coexisting substance to be measured, which results in a change in the fluorescence intensity of MG. Appear. Therefore, detection and quantification of the substance to be measured can be performed by measuring the change in the fluorescence intensity of MG.
- the above-described antigen-antibody reaction according to the present invention is reversible, contrary to the conventional general knowledge that the antigen-antibody reaction is irreversible. Therefore, the fluorescence intensity of MG fluctuates in response to the change in the amount of the substance to be measured, and by measuring the change in the fluorescence intensity, the substance to be measured can be continuously analyzed in real time.
- a calibration curve indicating the relationship between the fluorescence intensity and the concentration of the substance to be measured is obtained in advance before the measurement of the actual sample.
- a preferred embodiment of a method for creating a calibration curve according to the present invention will be described in detail based on a flowchart shown in FIG.
- an antibody dye solution Am1 is prepared (S101), which contains the dye, which changes from non-fluorescent to fluorescent upon binding, at a predetermined concentration (antibody concentration: ⁇ , dye concentration: ⁇ ).
- the solvent used is not particularly limited, but a buffer having a pH around neutral (preferably pH 6.5 to 7.5) is preferable. Examples of such a solvent include phosphate buffered saline. Can be
- the antibody dye solution is put into a cell for fluorescence measurement, and set in a fluorescence spectrophotometer in which the excitation light wavelength and the fluorescence wavelength are set to predetermined values according to the dye and the like to be used.
- the temperature of the cell holder is maintained at a constant temperature, and the holding temperature is preferably in the range of 25 to 37 ° C. Further, it is preferable to stir the solution in the cell for a predetermined time.
- a standard solution B n m 1 containing analyte at a predetermined concentration ( ⁇ ⁇ ⁇ ) was added to the solution in the cell, resulting mixed solution was stirred for a predetermined time dye
- the antigen-antibody reaction between the substance to be measured and the antibody is allowed to proceed (S103, mixing step).
- the solvent used for the standard solution is not particularly limited, but a buffer having near neutrality of H (for example, phosphate buffered saline) is preferable, similarly to the solvent used for the antibody dye solution.
- the mixed solution in the cell is irradiated with excitation light having a predetermined excitation light wavelength, and the intensity of fluorescence having a predetermined fluorescence wavelength emitted from the mixed solution is measured.
- a specific method for measuring the radiation and the fluorescence intensity of the excitation light is not particularly limited, the average value or the integration value of the fluorescence intensity during a given measurement time is preferably acquired as a fluorescence intensity measurements I n .
- the fluorescence intensity in the state where the substance to be measured is not added is set as a blank, and the value obtained by subtracting the blank value from the actual measurement value of the fluorescence intensity may be used as the measurement value I n of the fluorescence intensity (in this case, The Planck value should be subtracted from the measured value after correcting for the volume change accompanying the addition of the standard solution, etc.).
- the fluorescence intensity correction value ⁇ ⁇ ′ when the order ⁇ thus obtained is 1 to ⁇ , the fluorescence intensity correction value ⁇ ⁇ , Create a calibration curve showing the relationship between and the concentration of the substance to be measured ⁇ ⁇ '(S109, calibration curve creation process).
- a specific method for converting these numerical values into a calibration curve is not particularly limited, a known method such as a least squares method is appropriately used to obtain a calibration curve with higher accuracy.
- an antibody dye solution Am1 containing an antibody and the dye which changes from non-fluorescent to fluorescent when bound to the antibody at predetermined concentrations is prepared (S201) ).
- the solvent to be used is not particularly limited, but a buffer having a neutral pH (for example, phosphate buffered saline) is preferable as in the case of the solvent used for preparing the calibration curve.
- the antibody concentration and the dye concentration in the antibody dye solution are set to ⁇ and ⁇ / ⁇ , respectively, as in the case where the calibration curve was prepared.
- this antibody dye solution is put into a fluorescence measurement cell, and set in a fluorescence spectrophotometer in which the excitation light wavelength and the fluorescence wavelength are set to predetermined values, respectively, in the same manner as when the calibration curve was prepared.
- the temperature of the cell holder is maintained at the same temperature as when the calibration curve was prepared, and the temperature is preferably in the range of 25 to 37 ° C. Further, it is preferable that the solution in the cell is stirred for a predetermined time.
- analyte solution a body fluid or the like to be measured may be used as it is, or may be a solution diluted by a predetermined factor with a solvent.
- the solvent used for such dilution is not particularly limited, but is preferably a buffer having a neutral pH (for example, phosphate buffered saline), similarly to the solvent used for the antibody dye solution.
- the excitation light having a predetermined wavelength of the excitation light by irradiating the excitation light having a predetermined wavelength of the excitation light to the mixed solution in the cell, taking measurements I n by measuring the intensity of the fluorescence having a predetermined fluorescence wavelength emitted from the mixed solution (S204, measurement step).
- the specific method of irradiating the excitation light and measuring the fluorescence intensity is not particularly limited, but the fluorescence intensity measurement value ⁇ ⁇ is the average value of the fluorescence intensity during a predetermined measurement time as in the case of creating the calibration curve. And integral values are preferably obtained.
- I! 5 ⁇ , ⁇ ⁇ ( ⁇ + ⁇ ,) / A ⁇ (3)
- the measurement target substance in the mixed solution thus determined is From the density chi [pi ', can it to calculate the concentration ⁇ ⁇ ⁇ of analyte in the analyte solution B n m 1 (S 20 7 ).
- the calculation formula for calculating the concentration of the target substance in the test solution is given by the following formula (4):
- the above-described calculation of the fluorescence intensity correction value I ⁇ ′ (S 205 ), the calculation of the concentration ⁇ ⁇ ′ of the substance to be measured in the mixed solution (S 206), and the test solution calculation of concentration chi [pi of the measurement target substance in (S 207) is equivalent to the calculation process according to the present invention.
- the concentration of the target substance ⁇ ⁇ in the analyte solution can be measured.
- the antigen-antibody reaction according to the present invention is reversible as described above, It is also possible to measure another analyte solution continuously.
- ⁇ 2 ⁇ 2 'X (A + Bi + B one ( ⁇ , ⁇ ,) ⁇ / ⁇ 2 (4)''
- the antigen-antibody reaction since the antigen-antibody reaction is used, highly selective and highly selective separation can be performed by its specific molecular recognition function. However, it is possible to selectively and simply measure the target substance without removing impurities by fluorescence analysis. And, contrary to the conventional technical common sense that the antigen-antibody reaction is irreversible, since the antigen-antibody reaction according to the present invention is reversible, the fluorescence intensity fluctuates (increases) in response to the fluctuation of the amount of the substance to be measured. Or inhibition) can be used for continuous analysis in real time.
- the main reagents and experimental animals used in the examples are as follows. Malachite green (MG, manufactured by Aldrich Chemical Company, Inc.), malachite green sothiosinate (MGITC, manufactured by Molecular Probes Inc.), auramine 0 (A0, manufactured by Aldrich Chemical Company, Inc.), dimethyl sulfoxide (DMS0, Insulin (porcine, manufactured by Wako Pure Chemical Industries, Ltd.), SDS (Sodium Dodecyl Sulfate, manufactured by Wako Pure Chemical Industries, Ltd.), anti-porcine insulin antibody (immune animal Guinea Pig, Sigma) Guinea pigs (Crj; Hartley, Os, 3 weeks old, SPF, weight: 225-240 g, manufactured by Nippon Charis Riva Co., Ltd.), anesthetic (NEMBUTAL Sodium Solution, 50 mg / ml Dynabot) Co., Ltd.), RAS (Ribi Adjuvant System MPL + TDM + CWS Emulsion, R-730 (man
- washing buffer phosphate buffered saline, pH 7.2 (+) 0.05 ° /. Tween 20
- blocking buffer phosphate buffered saline
- Water pH 7.2 0.5% Gelatin
- 96-well microtiter plate manufactured by ELISA TESTPLATE F-FORM '2X8 F-STRIPS BINDUNG, greiner
- peroxidase-labeled goat anti-guinea pig IgG antibody Peroxidase-labeled Goat anti-Guinea Pig
- the main devices used in the examples are as follows. Plate reader (BI0-RAD MODEL 3550 MICR0PLATE READER), centrifuge (HITACHI SCR18B, manufactured by Hitachi, Ltd.), centrifuge rotor (RPR-18-3, manufactured by B Ritsumeisho), centrifuge (Labnet FORCE 7, Labnet International Inc.) ), Centrifuge (K0KUSAN MODEL H-103RS, Domestic Centrifuge Co., Ltd.), Vortex Mixer (AUTOMATIC MIXER S-100, TAITEC Co., Ltd.), Fluorescence Spectrophotometer (Fluorolog, manufactured by Instruments SA Inc.) ), Circulator (BU150P, manufactured by Yamato Scientific Co., Ltd.), micro-rotor (manufactured by Iuchi Seimeido), fluorescence measurement cell (manufactured by Inuchi Seimeido), high-performance liquid chromatography (LaChrom system interface D-7000, UV detection Vessel D-7400, pump D-7
- the protein-containing sample was concentrated by centrifugation at 3,000 X g using a sample pretreatment cartridge (ULTRACENT-30 or MINISENT-30) and a centrifuge (HITACHI SCR18B or Labnet Force 7). The solvent was replaced at the same time as the centrifugal concentration.
- the protein concentration of the sample was determined by using a commercially available reagent kit (BCA Protein Assay Reagent Kit, manufactured by PIERCE) and a standard protein solution (Pima IgG standard solution, concentration 2 mg Zm1, IramunoPure Horse IgG Standard, PIERCE) and quantified by the BCA method.
- BCA Protein Assay Reagent Kit manufactured by PIERCE
- a standard protein solution Pura IgG standard solution, concentration 2 mg Zm1, IramunoPure Horse IgG Standard, PIERCE
- a protein sample if necessary: diluted with PB
- a standard protein solution dilution series 25 to: L500 ⁇ g / m 1
- PB a standard curve plank sample
- MG-Ins complex a covalently bound antigen (MG-Ins complex) of malachite green (MG) and insulin (Ins) were performed as follows. That is, 4.7 mg of insulin and 0.6 mg of malachite green isothiocyanate (MGITC) dissolved in 20 ⁇ l of dimethyl sulfoxide were dissolved in 2 ml of 0.1 M sodium carbonate buffer (pH 9.8). ), And the container was stirred overnight at 4 ° C while shielding the light with an aluminum wheel. In this reaction, malachite green isothiosinate binds to the amino group of insulin, and an MG-Ins complex is obtained.
- MMITC malachite green isothiocyanate
- reaction solution was gel-eluted with a gel filtration column (Econo-Pac10DG, BI0-) equilibrated with 0.1 M sodium phosphate buffer (PB, pH 7.0). RAD) and 4ml PB The fraction was eluted from the column to obtain an MG-Ins fraction (about 1. Smg / ml).
- the MG-Ins fraction, 330 ⁇ l, and 1.7 ml of physiological saline were added to a vial of RAS, and vigorously stirred with a vortex mixer to prepare an emulsion of the antigen and adjuvant.
- guinea pigs were anesthetized with an anesthetic (NEMBUTAL) (dose: 15 m 1 / kg), and the above-mentioned emulsion was applied to the neck at 0.5 ml / mouse (subcutaneous injection (0.5 lm). l x 4 points) and intraperitoneal administration (0.1 ml)).
- NEMBUTAL anesthetic
- booster immunization was performed by administering the same amount of antigen together with an adjuvant three times at weekly intervals.
- guinea pigs were laparotomized after ether anesthesia, and whole blood was collected from the renal vena cava.
- the obtained blood was collected in a 10 ml test tube and heated to 37 ° C. in an incubator to form a blood clot. Thereafter, the blood clot was separated by centrifugation (30000 rpm, 4 ° C, 10 min) using a centrifuge (K0KUSAN MODEL H-103RS) to obtain an antiserum.
- a centrifuge K0KUSAN MODEL H-103RS
- the antibody titer of the antiserum was measured by an enzyme immunoassay. First, 6.3 ml of the antigen-coating buffer was added to 700 ⁇ l of the MG-Ins fraction, and 0.1 ml was dispensed into each well of a 96-well microtiter plate at 4 ° C. After standing overnight, the antigen (MG-Ins complex) was adsorbed and coated on the inner surface of each well of the plate. Thereafter, the antigen solution in the plate was removed, and 0.1 ml of a washing buffer was added to each well to wash the wells.
- the antiserum was diluted with PB to prepare a dilution series (dilution ratio: 500 to 320,000 times).
- a control guinea pig serum not treated with antigen was used.
- the antibody titer of this antiserum dilution series substantially corresponds to an antibody titer of 100 to 6400-fold dilution.
- 0.1 ml of each of these antiserum dilution series and control serum dilution was added to each well of the above plate, and the mixture was allowed to stand at 4 ° C. overnight to allow the antigen-antibody reaction to proceed.
- antiserum of each guinea pig showed stronger antibody activity than the control serum up to 800-fold or 1600-fold dilution, respectively, and the antiserum specific to the MG-Ins complex.
- a mixture of the antisera of four such guinea pigs (hereinafter referred to as “anti-MG-Ins serum”) was used in the following experiments.
- a resin on which protein A that binds specifically to IgG is immobilized (rProtein A Sepharose Fast Flow (Pharmacia Biotech AB) 0.7 ml) is packed in a plastic column (inner diameter about 7 mm, length about 8 cm) ( The column was washed with 3 ml of PB. [0100] Next, 1 ml of anti-MG-Ins serum was diluted with 1 ml of PB, and a cartridge type filter (0.45 ⁇ , Myshiyori Disc W-25-5, attached to a 5 ml disposable syringe) was used. The fine particles were removed through Tosoh Corporation.
- IgG was digested with the digestive enzyme papain to prepare Fab. That is, first, 8.7 mg of immobilized papain was placed in an eppendorf tube having a volume of 2.2 ml, 200 ⁇ l of ⁇ was added thereto, and the mixture was stirred, centrifuged, and the supernatant was removed to wash the immobilized papain. After repeating this washing twice, the immobilized papain was suspended in 1 ml of 2 OmM phosphate buffer ( ⁇ 7.0, (+) 1 OmM EDTA (+) 2 OmM cysteine).
- anti-MG-Ins Fabj fraction containing Fab of anti-MG-Ins antibody
- the fluorescent spectrum of MG when MG was bound to the anti-MG-Ins Fab by an antigen-antibody reaction was measured as follows. That is, both components were mixed so that the anti-MG-Ins Fab concentration was 0.955 ⁇ M and the MG concentration was 0.907 / iM (the solvent was phosphate buffered saline (pH 7.2, PBS)). The mixture was stirred at 25 ° C for 5 minutes to allow the antigen-antibody reaction to proceed.
- the fluorescence spectrum emitted from the mixed solution under the conditions of an excitation light wavelength of 620 nm, a fluorescence wavelength of 630 to 750 nm, and a band width of 5 nm for both the excitation side and the fluorescence side was used. It was measured. The background of the phosphate buffered saline measured under the same conditions was subtracted from the obtained raw data of the fluorescence spectrum, and the fluorescence spectrum corrected by the instrument function is shown in Fig. 11. It was confirmed that malachite green, which was substantially non-fluorescent in the aqueous solution, turned to fluorescent by binding to the anti-MG-Ins Fab.
- the preferred value of the relative amount of the antibody and the dye that is, the value at which the dye does not saturate the antibody and the relatively strong fluorescence of the dye is obtained, -For the Ins Fab concentration of 1 ⁇ , the MG concentration of ⁇ .
- the relative value may be different each time the polyclonal antibody is prepared, and may be apparently different depending on the purified purity of the prepared Fab even from the same polyclonal antibody.
- a calibration curve showing the relationship between the insulin concentration and the fluorescence intensity was created as follows. Since the used insulin contains zinc, it forms an aggregate of several molecules. Therefore, it was dissolved in PB containing 0.1% SDS in final concentration to dissociate the aggregate. Thereafter, the obtained insulin solution was subjected to a gel filtration column (Fast Desaliting column HR 10/10, manufactured by Pharmacia) equilibrated with PBS, and the SDS removed from the insulin solution was used in the following quantification. .
- the fluorescence spectrophotometer was set to an excitation light wavelength of 620 nm and an emission wavelength of 650 nm, and the temperature of the cell holder was kept at a constant temperature (25 ° C).
- the solution in the cell was irradiated with excitation light, the fluorescence intensity of MG emitted from the solution was measured for 30 seconds, and the average value of the fluorescence intensity per second (measured fluorescence intensity: I was determined.
- the fluorescence intensity when the insulin concentration was 0 ⁇ was defined as a blank, and the value obtained by subtracting the blank from the actual measured value was used as the measured value.
- ⁇ 2 ' ⁇ ⁇ ( ⁇ 1 + ⁇ 2 ) / (A + B! + B ⁇ (2)''.
- the test solution of the actual sample is a body fluid, its concentrated solution, or ⁇
- the fluorescence spectrophotometer was set at an excitation light wavelength of 620 nm and a fluorescence wavelength of 650 mn, and the temperature of the cell holder was kept at a constant temperature (25 ° C).
- test solution was added to the solution in the cell with 201 (B ⁇ 2.00 ml), and the mixture was stirred with a microrotator for 5 minutes to allow the antigen-antibody reaction to proceed (S203) ).
- the obtained fluorescence intensity measurement value () is corrected using the following formula (correction according to the volume change accompanying the addition of the analyte solution), and the volume change correction value (fluorescence intensity correction value:
- the insulin concentration in the test solution was determined using the following formula (S207).
- X 2 ⁇ X 2 , X ( ⁇ + ⁇ ⁇ ⁇ ⁇ -( ⁇ , ⁇ ⁇ ,) ⁇ ZB 2 (4) ',
- the kd of AO is larger than the kd of insulin, in which case, contrary to Example 1, the presence of insulin causes inhibition of fluorescence, and a negative correlation between insulin concentration and fluorescence intensity.
- the present inventor speculated that the relationship could be established. Therefore, in order to quantify insulin based on such a negative correlation between the insulin concentration and the fluorescence intensity, the following test was performed using AO instead of MG.
- the fluorescence spectrum of AO when AO was bound to anti-MG_Ins IgG by an antigen-antibody reaction was measured as follows. That is, mix both components so that the concentration of anti-MG-Ins IgG becomes 1 / iM and the concentration of AO becomes 1 ⁇ M (solvent is phosphate buffered saline (pH 7.2, PBS)), and reach 25 ° C. The mixture was stirred for 5 minutes to allow the antigen-antibody reaction to proceed.
- the anti-MG-Ins Fab concentration was 2 ⁇
- 0.4 ⁇ of auramine O was used instead of 0.4 M malachite green
- the excitation light wavelength was 400 nm
- the fluorescence was Except for the point where the wavelength was changed to 520 nm, the insulin concentration (X) in the test solution was determined in the same manner as in [1-10-2] above.
- the obtained insulin concentration in the test solution was 0.26 XM), which was confirmed to be consistent with the insulin concentration in the test solution determined by another method (BCA method).
- Insulin and anti-porcine insulin IgG are repeatedly added to a solution containing anti-MG-Ins Fab and auramine O, and the free insulin concentration fluctuates within the same sample.
- the following experiment was conducted to confirm that the measured values of the method of the present invention change following the change, that is, that the antigen-antibody reaction according to the present invention is reversible and enables real-time analysis.
- the measurement of the fluorescence intensity was performed in the same manner as in [2-2-1] described above, and the obtained results are shown in FIG.
- the antigen-antibody reaction according to the present invention is reversible, and the measured value (fluorescence intensity) of the method of the present invention is dependent on the fluctuation (increase / decrease) in the amount of the analyte. It was confirmed to follow reversibly.
- the measured value (fluorescence intensity) of the method of the present invention has a correlation with the amount of the measurement object, it was confirmed that the measurement object can be measured in real time by measuring the change in the fluorescence intensity. Was done.
- a fluorescence analysis method capable of simply and continuously analyzing (including imaging) a substance in a living body easily and with high sensitivity using an antigen-antibody reaction in real time. Becomes possible.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60328808T DE60328808D1 (de) | 2002-09-19 | 2003-09-18 | Fluoreszenzanalyseverfahren mit verwendung eines fluoreszenzantikörpers |
AT03797673T ATE439593T1 (de) | 2002-09-19 | 2003-09-18 | Fluoreszenzanalyseverfahren mit verwendung eines fluoreszenzantikörpers |
EP03797673A EP1550871B1 (en) | 2002-09-19 | 2003-09-18 | Fluorescence analysis method with the use of fluorescent antibody |
JP2004537606A JP4266367B2 (ja) | 2002-09-19 | 2003-09-18 | 蛍光化抗体を用いた蛍光分析方法 |
AU2003264497A AU2003264497A1 (en) | 2002-09-19 | 2003-09-18 | Fluorescence analysis method with the use of fluorescent antibody |
US11/083,084 US8574925B2 (en) | 2002-09-19 | 2005-03-18 | Fluorescence analysis method using fluorescent-activating antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002273833 | 2002-09-19 | ||
JP2002-273833 | 2002-09-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/083,084 Continuation-In-Part US8574925B2 (en) | 2002-09-19 | 2005-03-18 | Fluorescence analysis method using fluorescent-activating antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004027424A1 true WO2004027424A1 (ja) | 2004-04-01 |
Family
ID=32024969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011926 WO2004027424A1 (ja) | 2002-09-19 | 2003-09-18 | 蛍光化抗体を用いた蛍光分析方法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1550871B1 (ja) |
JP (1) | JP4266367B2 (ja) |
KR (1) | KR101027213B1 (ja) |
CN (1) | CN100552452C (ja) |
AT (1) | ATE439593T1 (ja) |
AU (1) | AU2003264497A1 (ja) |
DE (1) | DE60328808D1 (ja) |
WO (1) | WO2004027424A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005482A1 (de) * | 2003-07-09 | 2005-01-20 | Schering Ag | Emitter-bindende peptide die eine veränderung der spektralen emissionseigenschaften des emitters bewirken |
WO2013065314A1 (ja) * | 2011-11-02 | 2013-05-10 | ウシオ電機株式会社 | 蛍光標識抗体可変領域含有ポリペプチド複合体を用いた蛍光免疫測定方法 |
WO2015125851A1 (ja) * | 2014-02-19 | 2015-08-27 | 国立大学法人京都大学 | 神経伝達物質受容体のリガンドスクリーニングシステムの開発 |
CN111579540A (zh) * | 2020-05-06 | 2020-08-25 | 中南民族大学 | 一种枸杞碳点检测三苯甲烷类化合物的方法 |
CN114858767A (zh) * | 2022-04-11 | 2022-08-05 | 江西省农业科学院农产品质量安全与标准研究所 | 一种利用CdTe量子点检测喹乙醇的荧光免疫分析方法 |
US11630106B2 (en) | 2017-05-19 | 2023-04-18 | Philip Morris Products S.A. | Diagnostic test for distinguishing the smoking status of a subject |
WO2023229015A1 (ja) * | 2022-05-26 | 2023-11-30 | 富士レビオ株式会社 | 測定方法及び測定装置 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101802622B (zh) | 2007-11-08 | 2013-10-23 | 松下电器产业株式会社 | 分析用器件及使用该器件的分析方法 |
KR100958198B1 (ko) * | 2008-06-18 | 2010-05-14 | 고려대학교 산학협력단 | 실시간 연속 검출장치 |
JP5075150B2 (ja) * | 2009-03-17 | 2012-11-14 | 富士フイルム株式会社 | 検出方法および検出システム |
DE102009024943A1 (de) | 2009-06-10 | 2010-12-16 | W.O.M. World Of Medicine Ag | Bildgebungssystem und Verfahren zur fluoreszenz-optischen Visualisierung eines Objekts |
KR101309789B1 (ko) * | 2011-01-26 | 2013-09-23 | (주)프로테옴텍 | 티로신 산화물이 결합된 바이오 물질을 포함하는 단백질 검출용 조성물 |
WO2017143347A1 (en) * | 2016-02-19 | 2017-08-24 | San Diego State University Foundation | Applications of optical detection of low-level chemical and biological substances by nonlinear laser wave mixing in medicine and food safety |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0348765A (ja) * | 1989-07-18 | 1991-03-01 | Matsushita Electric Ind Co Ltd | 免疫的検出用物質及び免疫的検出法 |
JPH095324A (ja) * | 1995-03-27 | 1997-01-10 | Hamamatsu Photonics Kk | 蛍光化抗血清およびIgG画分 |
JPH11183477A (ja) * | 1997-12-24 | 1999-07-09 | Hamamatsu Photonics Kk | 蛍光免疫測定方法 |
US6437099B1 (en) * | 1998-01-07 | 2002-08-20 | Hamamatsu Photonics K.K. | Fluorescene—activating antisera and IgG fraction therefrom |
-
2003
- 2003-09-18 EP EP03797673A patent/EP1550871B1/en not_active Expired - Lifetime
- 2003-09-18 DE DE60328808T patent/DE60328808D1/de not_active Expired - Lifetime
- 2003-09-18 JP JP2004537606A patent/JP4266367B2/ja not_active Expired - Fee Related
- 2003-09-18 WO PCT/JP2003/011926 patent/WO2004027424A1/ja active Application Filing
- 2003-09-18 KR KR1020057002976A patent/KR101027213B1/ko not_active IP Right Cessation
- 2003-09-18 AU AU2003264497A patent/AU2003264497A1/en not_active Abandoned
- 2003-09-18 CN CNB038223597A patent/CN100552452C/zh not_active Expired - Fee Related
- 2003-09-18 AT AT03797673T patent/ATE439593T1/de not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0348765A (ja) * | 1989-07-18 | 1991-03-01 | Matsushita Electric Ind Co Ltd | 免疫的検出用物質及び免疫的検出法 |
JPH095324A (ja) * | 1995-03-27 | 1997-01-10 | Hamamatsu Photonics Kk | 蛍光化抗血清およびIgG画分 |
JPH11183477A (ja) * | 1997-12-24 | 1999-07-09 | Hamamatsu Photonics Kk | 蛍光免疫測定方法 |
US6437099B1 (en) * | 1998-01-07 | 2002-08-20 | Hamamatsu Photonics K.K. | Fluorescene—activating antisera and IgG fraction therefrom |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005482A1 (de) * | 2003-07-09 | 2005-01-20 | Schering Ag | Emitter-bindende peptide die eine veränderung der spektralen emissionseigenschaften des emitters bewirken |
WO2005005483A1 (de) * | 2003-07-09 | 2005-01-20 | Schering Ag | Emitter-bindende peptide, die eine veränderung der spektralen emissionseigenschaften des emitters bewirken |
EA010289B1 (ru) * | 2003-07-09 | 2008-08-29 | Шеринг Акциенгезельшафт | Связывающиеся с эмиттером пептиды, которые вызывают изменение спектральных характеристик эмиссии эмиттера |
WO2013065314A1 (ja) * | 2011-11-02 | 2013-05-10 | ウシオ電機株式会社 | 蛍光標識抗体可変領域含有ポリペプチド複合体を用いた蛍光免疫測定方法 |
JPWO2013065314A1 (ja) * | 2011-11-02 | 2015-04-02 | ウシオ電機株式会社 | 蛍光標識抗体可変領域含有ポリペプチド複合体を用いた蛍光免疫測定方法 |
WO2015125851A1 (ja) * | 2014-02-19 | 2015-08-27 | 国立大学法人京都大学 | 神経伝達物質受容体のリガンドスクリーニングシステムの開発 |
JPWO2015125851A1 (ja) * | 2014-02-19 | 2017-03-30 | 国立大学法人京都大学 | 神経伝達物質受容体のリガンドスクリーニングシステムの開発 |
US11630106B2 (en) | 2017-05-19 | 2023-04-18 | Philip Morris Products S.A. | Diagnostic test for distinguishing the smoking status of a subject |
CN111579540A (zh) * | 2020-05-06 | 2020-08-25 | 中南民族大学 | 一种枸杞碳点检测三苯甲烷类化合物的方法 |
CN111579540B (zh) * | 2020-05-06 | 2023-05-23 | 中南民族大学 | 一种枸杞碳点检测三苯甲烷类化合物的方法 |
CN114858767A (zh) * | 2022-04-11 | 2022-08-05 | 江西省农业科学院农产品质量安全与标准研究所 | 一种利用CdTe量子点检测喹乙醇的荧光免疫分析方法 |
WO2023229015A1 (ja) * | 2022-05-26 | 2023-11-30 | 富士レビオ株式会社 | 測定方法及び測定装置 |
Also Published As
Publication number | Publication date |
---|---|
CN100552452C (zh) | 2009-10-21 |
KR101027213B1 (ko) | 2011-04-06 |
EP1550871A4 (en) | 2007-01-03 |
ATE439593T1 (de) | 2009-08-15 |
DE60328808D1 (de) | 2009-09-24 |
AU2003264497A1 (en) | 2004-04-08 |
JPWO2004027424A1 (ja) | 2006-01-19 |
EP1550871A1 (en) | 2005-07-06 |
JP4266367B2 (ja) | 2009-05-20 |
CN1682112A (zh) | 2005-10-12 |
KR20050058431A (ko) | 2005-06-16 |
EP1550871B1 (en) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102735833B (zh) | 甲状腺过氧化物酶抗体均相发光免疫分析试剂盒及其检测方法 | |
JPH0421818B2 (ja) | ||
WO2004027424A1 (ja) | 蛍光化抗体を用いた蛍光分析方法 | |
US8058011B2 (en) | Method for the measurement of endocrine substances in an analyte | |
CN107533052B (zh) | 在免疫测定中重复使用测试探针和试剂的方法 | |
US8574925B2 (en) | Fluorescence analysis method using fluorescent-activating antibodies | |
WO2006025401A1 (ja) | 抗原の測定方法及びそのための試薬 | |
US6437099B1 (en) | Fluorescene—activating antisera and IgG fraction therefrom | |
AU676469B2 (en) | Method for the elimination of non-specific reactions in immunoassays | |
US4624927A (en) | Reagent for determination of blood coagulation factor XIII | |
JPH02159562A (ja) | 抗原に対してクラス特異的抗体の測定法及びこのために好適な試薬 | |
JP3662333B2 (ja) | 蛍光化抗血清およびIgG画分 | |
JPH0421819B2 (ja) | ||
JPH08304406A (ja) | カリブレーターマトリックス | |
JP2004144687A (ja) | 物質の測定方法 | |
JP3674529B2 (ja) | 吸光ラベルを用いる尿中疾患マーカータンパク質の迅速・簡易検出方法 | |
JP2694809B2 (ja) | 酵素免疫測定方法及び酵素免疫センサ | |
JPS63106561A (ja) | 免疫分析試薬 | |
JP4153068B2 (ja) | 蛍光免疫測定方法 | |
JP3501381B2 (ja) | リウマチ因子測定試薬 | |
JPH0566222A (ja) | 物質の分析方法 | |
JPH1144688A (ja) | 蛍光偏光免疫測定法 | |
JPH08313530A (ja) | 総ヘモグロビン測定方法及び測定キット | |
JPH07159404A (ja) | スピンラベルしたビオチンを用いた物質の測定方法 | |
JPS6082966A (ja) | 抗原の定量法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004537606 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057002976 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11083084 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038223597 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003797673 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002976 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003797673 Country of ref document: EP |